Pharming

August 13, 2019

Novartis cast-off gives Pharming a gap-filler

Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?

October 12, 2018

Cost-effectiveness doubts could hit Shire’s Takhzyro launch

A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.

September 19, 2018

The other shoe drops for Pharming

A US complete response letter leaves Ruconest at the mercy of rivals like Shire.

August 09, 2018

Shire dodges pricing questions as lanadelumab’s big day nears

Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?

March 09, 2018

Snippet roundup: A fillip for Pfizer but Merck KGaA comes under pressure

November 22, 2016

Pharming bets the house on Ruconest

August 12, 2016

Snippet roundup: Lilly pill slips, Mek inhibitors reach limit, Myriad buys

August 12, 2016

Interview – Pharming’s last chance lies with solo strategy

August 10, 2016

A new Valeant starts to take shape, and it's still not pretty

July 15, 2016

Snippet roundup: Immuno-oncology hopes for Parkinson's class, Coherus climbs

February 24, 2016

The US FDA shows its teeth

Load More